Capricor Therapeutics’ (CAPR) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $77.00 price objective on the biotechnology company’s stock.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR opened at $12.88 on Monday. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The company has a 50 day simple moving average of $14.14 and a two-hundred day simple moving average of $14.46. The company has a market capitalization of $585.65 million, a price-to-earnings ratio of -12.15 and a beta of 4.10.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Summit Investment Advisors Inc. increased its stake in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter valued at approximately $68,000. AlphaQuest LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund increased its position in shares of Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 5,000 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.